New immunotherapy flotetuzumab tested in kids with Tough-to-Treat leukemia
NCT ID NCT04158739
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a drug called flotetuzumab in children and young adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. Flotetuzumab is an immunotherapy designed to help the body's immune cells find and attack cancer cells. The main goals are to find the safest dose and understand side effects, not yet to prove it works as a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
flotetuzumab (an immunotherapy drug that helps immune cells attack cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for children with hard-to-treat AML.
What could go wrong
This is a very early (Phase 1) trial with only 16 participants, so it is mainly checking safety and dosing. The drug may not work well or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030, United States
-
C S Mott Children's Hospital
Ann Arbor, Michigan, 48109, United States
-
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia, 30329, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Alabama
Birmingham, Alabama, 35233, United States
-
Children's Hospital of Orange County
Orange, California, 92868, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Lurie Children's Hospital-Chicago
Chicago, Illinois, 60611, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Saint Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
UCSF Medical Center-Mission Bay
San Francisco, California, 94158, United States
-
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States